PFIZER INC (PFE)

US7170811035 - Common Stock

26.59  +0.03 (+0.11%)

Premarket: 26.61 +0.02 (+0.08%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PFIZER INC

NYSE:PFE (3/1/2024, 7:04:00 PM)

Premarket: 26.61 +0.02 (+0.08%)

26.59

+0.03 (+0.11%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap150.15B
Shares
PE14.53
Fwd PE11.59
Dividend Yield6.33%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PFE Daily chart

Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 83,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The firm operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK 10017

P: 12127332323

CEO: Albert Bourla

Employees: 83000

Website: https://www.pfizer.com/

PFE News

News Imagean hour ago - The Motley Fool3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in March

These high-octane income stocks, which sport a scorching-hot average yield of 8.84%, can fatten the wallets of patient investors.

News Imagean hour ago - The Motley FoolIs Novavax a Buy Now?

The stock has dropped 98% over the past three years.

News Image4 hours ago - Investor's Business DailyBridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?

BridgeBio will receive a tiered royalty on sales that begins at the low-30% range.

News Image13 hours ago - TheNewswire.comBNTX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class Period”), of the important March 12, 2024 lead plaintiff deadline.

News Image13 hours ago - NewMediaWireBNTX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

WHY: NEW YORK, NY - (NewMediaWire) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class Period”), of the important March 12, 2024 lead plaintiff deadline.

News Image20 hours ago - InvestorPlacePlan Ahead! 7 Stocks to Buy Before Any Market Downturn Occurs

While red ink in the broader equities space could hurt most entities, these stocks to buy for a market downturn might be resilient.

PFE Twits

Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example